



## **X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference**

January 19, 2022

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- [X4 Pharmaceuticals, Inc.](#) (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at B. Riley Securities Oncology Investor Conference on Friday, January 28, 2022.

### **Details are as follows:**

Conference: B. Riley Securities Oncology Investor Conference

Format: Fireside Chat

Date: Friday, January 28, 2022

Time: 1:00 PM ET

[Presentation Webcast Link](#)

A live webcast of the fireside chat from the B. Riley Securities Oncology Investor Conference will be available on the investors section of the X4 Pharmaceuticals' website at [www.x4pharma.com](http://www.x4pharma.com). After the live webcast, the event will remain archived on the X4 Pharmaceuticals' website for at least 30 days.

### **About X4 Pharmaceuticals**

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with immune system dysfunction. The company's lead candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor's ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, X4 believes that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Mavorixafor has already demonstrated clinical potential in a Phase 2 trial in people with WHIM syndrome, a rare PID. Its efficacy and safety continue to be evaluated in a global Phase 3 clinical trial in WHIM (fully enrolled) and in two Phase 1b clinical trials – one, as monotherapy in people with Severe Congenital Neutropenia (SCN) and other chronic neutropenia conditions, and another in combination with ibrutinib in people with Waldenström's macroglobulinemia, a rare B-cell lymphoma. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, to discover and develop additional product candidates. For more information, please visit [www.x4pharma.com](http://www.x4pharma.com).

### **Contacts:**

**Glenn Schulman, PharmD, MPH (corporate)**

VP, Investor Relations & Corporate Communications

[glenn.schulman@x4pharma.com](mailto:glenn.schulman@x4pharma.com)

(203) 494-7411

**Daniel Ferry (investors)**

Managing Director, LifeSci Advisors

[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)

(617) 430-7576

**Mónica Rouco Molina (media)**

Senior Account Executive, LifeSci Communications

[mroucomolina@lifescicomms.com](mailto:mroucomolina@lifescicomms.com)



Source: X4 Pharmaceuticals